Genflow to Attend Healthcare Conference

Core Insights - Genflow Biosciences Plc will attend the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, California, which is a significant event for the healthcare investment sector [1][2][3] Company Overview - Genflow Biosciences, founded in 2020, is a UK-based biotechnology company focused on developing gene therapies aimed at decelerating the aging process and promoting healthier, longer lives [5] - The company’s lead compound, GF-1002, targets the SIRT6 gene and has shown promising preclinical results [5] - Genflow is currently conducting a 12-month proof-of-concept clinical trial for its SIRT6-centenarian gene therapy in aged dogs, which began in March 2025 [5] Conference Participation - The J.P. Morgan Healthcare Conference is recognized as the most influential global investment gathering in the healthcare sector, providing a platform for industry leaders, innovators, and investors to connect [2][3] - Genflow's participation is aimed at engaging with potential partners, institutional investors, and pharmaceutical companies to advance its gene-therapy pipeline [2] Strategic Focus - Dr. Eric Leire, CEO of Genflow, emphasized the company's focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is expected to create strategic partnership opportunities in the longevity sector [4]